Bay­er wins OK for he­mo­phil­ia A treat­ment; Agenus sells off a slice of fu­ture roy­al­ties for $15M

→ Japan­ese of­fi­cials have ap­proved Bay­er’s he­mo­phil­ia A drug Jivi (BAY94-9027), a Fac­tor VI­II treat­ment.

Xo­ma is tap­ping in­to their line of cred­it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.